Does the media refer more to XERS or DFTX?

In the previous week, Definium Therapeutics had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Definium Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.20 beat Definium Therapeutics' score of 0.62 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MANE or XERS?

In the previous week, Veradermics had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Veradermics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.20 beat Veradermics' score of 0.31 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is XERS or INDV more profitable?

Indivior has a net margin of 26.65% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Xeris Biopharma -5.12% 338.21% 3.50% Indivior 26.65% -283.11% 36.85%

Does the media refer more to XERS or INDV?

In the previous week, Xeris Biopharma and Xeris Biopharma both had 2 articles in the media. Xeris Biopharma's average media sentiment score of 1.20 beat Indivior's score of 0.52 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xeris Biopharma (XERS) Competitors

$8.70 +0.10 (+1.16%)

As of 08/21/2026 04:00 PM Eastern

Compare

XERS vs. AMRX, DFTX, MANE, INDV, and CPRX

Should you buy Xeris Biopharma stock or one of its competitors? Xeris Biopharma's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Veradermics (MANE), Indivior (INDV), and Catalyst Pharmaceuticals (CPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Xeris Biopharma (NASDAQ:XERS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Xeris Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Xeris Biopharma currently has a consensus price target of $12.00, indicating a potential upside of 37.93%. Amneal Pharmaceuticals has a consensus price target of $17.67, indicating a potential downside of 1.36%. Given Xeris Biopharma's higher possible upside, equities research analysts clearly believe Xeris Biopharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Amneal Pharmaceuticals has a net margin of 5.05% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	5.43	$550K	-$0.11	N/A
Amneal Pharmaceuticals	$3.12B	1.83	$72.06M	$0.49	36.55

In the previous week, Xeris Biopharma had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 2 mentions for Xeris Biopharma and 0 mentions for Amneal Pharmaceuticals. Xeris Biopharma's average media sentiment score of 1.20 beat Amneal Pharmaceuticals' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Xeris Biopharma	Positive
Amneal Pharmaceuticals	Neutral

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 11 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Definium Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Xeris Biopharma has higher revenue and earnings than Definium Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	5.43	$550K	-$0.11	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Definium Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Definium Therapeutics	N/A	-84.01%	-63.66%

Xeris Biopharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xeris Biopharma presently has a consensus price target of $12.00, suggesting a potential upside of 37.93%. Definium Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 40.28%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Definium Therapeutics had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Definium Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.20 beat Definium Therapeutics' score of 0.62 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xeris Biopharma and Definium Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Veradermics?

Veradermics (NYSE:MANE) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Veradermics currently has a consensus price target of $153.00, indicating a potential upside of 48.07%. Xeris Biopharma has a consensus price target of $12.00, indicating a potential upside of 37.93%. Given Veradermics' stronger consensus rating and higher possible upside, analysts clearly believe Veradermics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veradermics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Xeris Biopharma	-5.12%	338.21%	3.50%

42.8% of Xeris Biopharma shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than Veradermics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Veradermics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Xeris Biopharma	$291.85M	5.43	$550K	-$0.11	N/A

In the previous week, Veradermics had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Veradermics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.20 beat Veradermics' score of 0.31 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xeris Biopharma beats Veradermics on 8 of the 14 factors compared between the two stocks.

How does Xeris Biopharma compare to Indivior?

Xeris Biopharma (NASDAQ:XERS) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Xeris Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

In the previous week, Xeris Biopharma and Xeris Biopharma both had 2 articles in the media. Xeris Biopharma's average media sentiment score of 1.20 beat Indivior's score of 0.52 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma currently has a consensus target price of $12.00, suggesting a potential upside of 37.93%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 22.50%. Given Xeris Biopharma's higher probable upside, equities research analysts clearly believe Xeris Biopharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Indivior has a net margin of 26.65% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Indivior	26.65%	-283.11%	36.85%

Indivior has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	5.43	$550K	-$0.11	N/A
Indivior	$1.24B	3.51	$210M	$2.79	13.22

Summary

Indivior beats Xeris Biopharma on 10 of the 15 factors compared between the two stocks.

How does Xeris Biopharma compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Catalyst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Xeris Biopharma	-5.12%	338.21%	3.50%

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, indicating a potential upside of 1.62%. Xeris Biopharma has a consensus price target of $12.00, indicating a potential upside of 37.93%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Xeris Biopharma had 2 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 2 mentions for Xeris Biopharma and 0 mentions for Catalyst Pharmaceuticals. Xeris Biopharma's average media sentiment score of 1.20 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
Xeris Biopharma	Positive

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Xeris Biopharma	$291.85M	5.43	$550K	-$0.11	N/A

Summary

Catalyst Pharmaceuticals beats Xeris Biopharma on 12 of the 17 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.59B	$12.51B	$7.36B	$12.84B
Dividend Yield	N/A	2.61%	2.54%	11.08%
P/E Ratio	-79.09	789.80	272.88	24.24
Price / Sales	5.43	766.93	621.86	100.14
Price / Cash	86.85	96.77	78.62	53.99
Price / Book	-174.00	11.89	13.05	6.20
Net Income	$550K	$2.81B	$3.47B	$348.59M
7 Day Performance	1.16%	1.77%	2.09%	0.08%
1 Month Performance	3.45%	3.85%	6.64%	3.88%
1 Year Performance	12.26%	6.56%	25.02%	16.98%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	3.7632 of 5 stars	$8.70 +1.2%	$12.00 +37.9%	+12.3%	$1.59B	$291.85M	N/A	290	Analyst Forecast
AMRX Amneal Pharmaceuticals	2.4209 of 5 stars	$18.42 +1.5%	$17.67 -4.1%	+86.8%	$5.80B	$3.02B	37.59	8,500
DFTX Definium Therapeutics	3.1212 of 5 stars	$45.26 +6.2%	$63.00 +39.2%	+340.7%	$5.73B	N/A	N/A	40	Analyst Forecast Options Volume
MANE Veradermics	2.2212 of 5 stars	$107.76 -4.4%	$153.00 +42.0%	N/A	$4.71B	N/A	N/A	19	News Coverage Insider Trade
INDV Indivior	3.8879 of 5 stars	$39.08 +0.2%	$45.17 +15.6%	+51.6%	$4.60B	$1.24B	14.01	1,051	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. AMRX, DFTX, MANE, INDV, and CPRX

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Summary

How does Xeris Biopharma compare to Definium Therapeutics?

Summary

How does Xeris Biopharma compare to Veradermics?

Summary

How does Xeris Biopharma compare to Indivior?

Summary

How does Xeris Biopharma compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. AMRX, DFTX, MANE, INDV, and CPRX

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Which has more volatility and risk, XERS or AMRX?

Do insiders and institutionals believe in XERS or AMRX?

Do analysts rate XERS or AMRX?

Is XERS or AMRX more profitable?

Which has higher earnings and valuation, XERS or AMRX?

Does the media prefer XERS or AMRX?

Summary

How does Xeris Biopharma compare to Definium Therapeutics?

Which has higher earnings and valuation, XERS or DFTX?

Is XERS or DFTX more profitable?

Which has more risk and volatility, XERS or DFTX?

Do institutionals & insiders have more ownership in XERS or DFTX?

Do analysts recommend XERS or DFTX?

Does the media refer more to XERS or DFTX?

Summary

How does Xeris Biopharma compare to Veradermics?

Do analysts rate MANE or XERS?

Is MANE or XERS more profitable?

Do institutionals and insiders believe in MANE or XERS?

Which has stronger earnings & valuation, MANE or XERS?

Does the media favor MANE or XERS?

Summary

How does Xeris Biopharma compare to Indivior?

Do insiders and institutionals have more ownership in XERS or INDV?

Which has more volatility and risk, XERS or INDV?

Does the media refer more to XERS or INDV?

Do analysts rate XERS or INDV?

Is XERS or INDV more profitable?

Which has preferable earnings and valuation, XERS or INDV?

Summary

How does Xeris Biopharma compare to Catalyst Pharmaceuticals?

Do insiders & institutionals believe in CPRX or XERS?

Is CPRX or XERS more profitable?

Do analysts rate CPRX or XERS?

Does the media favor CPRX or XERS?

Which has more volatility & risk, CPRX or XERS?

Which has higher earnings and valuation, CPRX or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools